Loading clinical trials...
Loading clinical trials...
Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Conditions
Interventions
Cyclophosphamide
Fludarabine
+2 more
Locations
1
China
Changhai Hospital
Shanghai, China
Start Date
October 21, 2021
Primary Completion Date
June 1, 2027
Completion Date
December 1, 2028
Last Updated
December 24, 2025
NCT02600949
NCT03050268
NCT06921928
NCT06423326
NCT07542041
NCT07283705
Lead Sponsor
Changhai Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions